Top of the morning to you. A spot of rain is descending on the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is mountain blueberry. Meanwhile, here are a few items of interest. Hope you have a smashing day, and, of course, do stay in touch. …
Workers at a plant in Baltimore manufacturing two Covid-19 vaccines accidentally conflated the ingredients several weeks ago, contaminating up to 15 million doses of Johnson & Johnson’s (JNJ) vaccine and forcing regulators to delay authorization of the plant’s production lines, The New York Times reports. The plant is run by Emergent BioSolutions (EBS), a manufacturing partner to both J&J and AstraZeneca (AZN), whose vaccine has yet to be authorized for use in the U.S. Federal officials attributed the mistake to human error.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
If memory serves (and it may not …), the BMS issue mentioned above raises echo’s of the so called “Synthes exception” in 2012 that J&J exercised successfully BUT the IRS later said would not be able to be exercised again. The timing of 9 years is instructive?